Literature DB >> 23294427

Next-generation sequencing - feasibility and practicality in haematology.

Alexander Kohlmann1, Vera Grossmann, Niroshan Nadarajah, Torsten Haferlach.   

Abstract

Next-generation sequencing platforms have evolved to provide an accurate and comprehensive means for the detection of molecular mutations in heterogeneous tumour specimens. Here, we review the feasibility and practicality of this novel laboratory technology. In particular, we focus on the utility of next-generation sequencing technology in characterizing haematological neoplasms and the landmark findings in key haematological malignancies. We also discuss deep-sequencing strategies to analyse the constantly increasing number of molecular markers applied for disease classification, patient stratification and individualized monitoring of minimal residual disease. Although many facets of this assay need to be taken into account, amplicon deep-sequencing has already demonstrated a promising technical performance and is being continuously developed towards routine application in diagnostic laboratories so that an impact on clinical practice can be achieved.
© 2013 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 23294427     DOI: 10.1111/bjh.12194

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  19 in total

1.  Archival bone marrow trephines are suitable for high-throughput mutation analysis using next generation sequencing technology.

Authors:  Britta Hasemeier; Robert Geffers; Stephan Bartels; Brigitte Schlegelberger; Hans Kreipe; Ulrich Lehmann
Journal:  Haematologica       Date:  2013-09       Impact factor: 9.941

2.  Getting personal with myelodysplastic syndromes: is now the right time?

Authors:  Nora Chokr; Alexander B Pine; Jan Philipp Bewersdorf; Rory M Shallis; Maximilian Stahl; Amer M Zeidan
Journal:  Expert Rev Hematol       Date:  2019-04-12       Impact factor: 2.929

3.  Impact of mutational variant allele frequency on prognosis in myelodysplastic syndromes.

Authors:  Lingxu Jiang; Lu Wang; Chuying Shen; Shuanghong Zhu; Wei Lang; Yingwan Luo; Hua Zhang; Wenli Yang; Yueyuan Han; Liya Ma; Yanling Ren; Xinping Zhou; Chen Mei; Li Ye; Weilai Xu; Haiyang Yang; Chenxi Lu; Jie Jin; Hongyan Tong
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

4.  Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease.

Authors:  A Kohlmann; N Nadarajah; T Alpermann; V Grossmann; S Schindela; F Dicker; A Roller; W Kern; C Haferlach; S Schnittger; T Haferlach
Journal:  Leukemia       Date:  2013-08-20       Impact factor: 11.528

5.  Inter-Laboratory Evaluation of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia.

Authors:  Karl Haslam; Mark A Catherwood; Edwina Dobbin; Anne Sproul; Stephen E Langabeer; Ken I Mills
Journal:  Mol Diagn Ther       Date:  2016-10       Impact factor: 4.074

Review 6.  Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable.

Authors:  Katerina Zoi; Nicholas C P Cross
Journal:  Int J Hematol       Date:  2014-09-12       Impact factor: 2.490

7.  Comprehensive Molecular Profiling of Archival Bone Marrow Trephines Using a Commercially Available Leukemia Panel and Semiconductor-Based Targeted Resequencing.

Authors:  Stephan Bartels; Elisa Schipper; Hans Heinrich Kreipe; Ulrich Lehmann
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

Review 8.  Cracking the Code of Human Diseases Using Next-Generation Sequencing: Applications, Challenges, and Perspectives.

Authors:  Vincenza Precone; Valentina Del Monaco; Maria Valeria Esposito; Fatima Domenica Elisa De Palma; Anna Ruocco; Francesco Salvatore; Valeria D'Argenio
Journal:  Biomed Res Int       Date:  2015-11-19       Impact factor: 3.411

Review 9.  Next generation sequencing: new tools in immunology and hematology.

Authors:  Antonio Mori; Sara Deola; Luciano Xumerle; Vladan Mijatovic; Giovanni Malerba; Vladia Monsurrò
Journal:  Blood Res       Date:  2013-12-24

10.  Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients.

Authors:  Vaclava Polivkova; Peter Rohon; Hana Klamova; Olga Cerna; Martina Divoka; Nikola Curik; Jan Zach; Martin Novak; Iuri Marinov; Simona Soverini; Edgar Faber; Katerina Machova Polakova
Journal:  PLoS One       Date:  2016-05-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.